US 8182838B2
· Morton
· 2012
[cited by applicant]
US 9630990B2
· Shetty
· 2017
[cited by examiner]
US 20020077283A1
· Sessa
· 2002
[cited by applicant]
CN 107405379A
· 2017
[cited by applicant]
JP 2005503321
· 2005
[cited by applicant]
JP 2018507867
· 2018
[cited by applicant]
KR 20050003416
· 2005
[cited by applicant]
WO WO02020768
· 2002
[cited by applicant]
WO WO2003016540
· 2003
[cited by applicant]
WO WO2003094890
· 2003
[cited by applicant]
WO WO2014145389
· 2014
[cited by applicant]
WO WO2016138413
· 2016
[cited by applicant]
WO WO2016138413A1
· 2016
[cited by examiner]
Markarian, Jennifer, Inhalation Drug Manufacturing, Pharmaceutical Technology, 42(4). Examiner Generated pdf. (Year: 2018).
[cited by examiner]
Loh et al., Overview of milling techniques for improving the solubility of poorly water-soluble drugs, Asian Journal of Pharmaceutical Science: 10: 255-274. (Year: 2015).
[cited by examiner]
Sou et al., Designing a multi-component spray-dried formulation platform for pulmonary delivery of biopharmaceuticals: The use of polyol, disaccharide, polysaccharide and synthetic polymer to modify solid-state properti…
[cited by examiner]
Li et al., L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders, European Journal of Pharmaceutics and Biopharmaceutics; 102: 132-141 (Year: 2016).
[cited by examiner]
Markarian, Optimizing Particle Engineering Methods for Inhalation Drug Products, Pharmaceutical Technology; 42(4). (Year: 2018).
[cited by examiner]
Anonymous: “Caveolin-1 scaffolding domain peptide—ALX-153-064—Enzo Life Sciences”, dated Aug. 28, 2018 (Aug. 28, 2018), pp. 1-2, XP055919016, Retrieved from the Internet: URL:http://web.archive.org/web/20180828064 451/h…
[cited by applicant]
Extended European Search Report issued in corresponding European Application No. 19859836.9, dated Jun. 3, 2022.
[cited by applicant]
Irngartinger, M et al. “Pulmonary delivery of therapeutic peptides via dry powder inhalation: Effects of micronisation and manufacturing.”
[cited by applicant]
Schmitz, Matthias et al. “Effect of cavtratin, a caveolin-1 scaffolding domain peptide, on oligodendroglial signaling cascades.”
[cited by applicant]
Vandana, K R et al. “An overview on in situ micronization technique—An emerging novel concept in advanced drug delivery.”
[cited by applicant]
Zhang, Yajie et al. “Development of an Excipient-Free Peptide Dry Powder Inhalation for the Treatment of Pulmonary Fibrosis.”
[cited by applicant]
Office Communication issued in corresponding Japanese Application No. 2021-538171, dated Jul. 7, 2023. English Translation.
[cited by applicant]
Surasarang et al., “Formulation for a novel inhaled peptide therapeutic for idiopathic pulmonary fibrosis.,”
[cited by applicant]
De Boer, Anne H., et al. “Dry powder inhalation: past, present and future.”
[cited by applicant]
Office Communication issued in corresponding Chinese Application No. 201980073144.0, dated Sep. 28, 2023. English Translation.
[cited by applicant]
Office Communication issued in corresponding European Application No. 19 859 836.9, dated Dec. 18, 2023. English Translation.
[cited by applicant]
Office Communication issued in corresponding Japanese Application No. 2021-538171, dated Dec. 4, 2023. English Translation.
[cited by applicant]
Phillips, E., et al. “Size reduction of peptides and proteins by jet-milling.”
[cited by applicant]
Shetty, Nivedita, et al. “Physical stability of dry powder inhaler formulations.”
[cited by applicant]
Yamashita, Chikamasa. “The present state and future of dry powder inhalation system.”
[cited by applicant]
Zhou, J. Y., Lan Zhang, and S. R. Mao. “Recent progress of dry powder inhalation of proteins and peptides.”
[cited by applicant]
“AFREZZA®”, Highlights of prescribing information, dated Feb. 2023.
[cited by applicant]
“ESUBERA®”, NDA 21-868 US Package Insert, dated Jan. 27, 2007.
[cited by applicant]
NCT04233814, “Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects”, dated Mar. 7, 2022, downloaded from ClinicalTrials.gov on Nov. 1, 2024.
[cited by applicant]
NCT05954988, “A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients”, dated Aug. 30, 2023, downloaded from ClinicalTrials.gov on Nov. 1, 2024.
[cited by applicant]
O'Callaghan, Christopher, and Peter W. Barry. “The science of nebulised drug delivery.” Thorax 52.Suppl 2 (1997): S31.
[cited by applicant]
Office Communication issued in corresponding Korean Application No. 10-2021-7010694, dated Nov. 11, 2024. English Translation.
[cited by applicant]
Aillon, Kristin L., et al. “Iodinated NanoClusters as an inhaled computed tomography contrast agent for lung visualization.”
[cited by applicant]
Chan, John Gar Yan, et al. “Advances in device and formulation technologies for pulmonary drug delivery.”
[cited by applicant]
Johnson, Elizabeth R., and Michael A. Matthay. “Acute lung injury: epidemiology, pathogenesis, and treatment.”
[cited by applicant]
King, Paul T. “Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer.”
[cited by applicant]
Office Communication issued in corresponding U.S. Appl. No. 18/434,731, dated Aug. 15, 2024.
[cited by applicant]
Rogliani, Paola, et al. “Optimizing drug delivery in COPD: the role of inhaler devices.”
[cited by applicant]
Rothe, Thomas et al. “Diagnosis and Management of Asthma—The Swiss Guidelines.”
[cited by applicant]
Welsh, Carolyn H., et al. “An international ISHLT/ATS/ERS clinical practice guideline: summary for clinicians. Bronchiolitis obliterans syndrome complicating lung transplantation.”
[cited by applicant]
Carvalho et al., “Influence of particle size on regional lung deposition—What evidence is there?”
[cited by applicant]
Hübner, R.-H et al., “Standardized quantification of pulmonary fibrosis in histological samples.”
[cited by applicant]
International Preliminary Report on Patentability issued in corresponding PCT Application No. PCT/US2019/050349, mailed on Mar. 25, 2021.
[cited by applicant]
International Search Report and Written Opinion issued in corresponding PCT Application No. PCT/US2019/050349, mailed on Dec. 11, 2019.
[cited by applicant]
Shetty S, et al. “Induction of p53 by urokinase in lung epithelial cells.”
[cited by applicant]
Tepper, J. S.; Kuehl, P. J.; Cracknell, S.; Nikula, K. J.; Pei, L.; Blanchard, J. D. Symposium Summary: “breathe In, Breathe Out, Its Easy: What You Need to Know about Developing Inhaled Drugs.”
[cited by applicant]